Biogen last year said it would ask the FDA to review its potential Alzheimer’s disease treatment, aducanamab, sometime in “early” 2020. The submission is being made under a rolling review, in which sections of an application are filed as they are completed rather than all at once.
Now the Cambridge, MA-based company says the regulatory filing will be complete in the third quarter, an unexpected delay for a drug developer vying to commercialize what could become the first therapy to change the course of the disease.
Executives at Biogen (NASDAQ: BIIB) announced the change Wednesday in tandem with the firm’s… Read more »
UNDERWRITERS AND PARTNERS
